Cargando…

Improving the American Diabetes Association Framework for individualizing treatment in older adults: evaluating life expectancy

INTRODUCTION: For older adults with type 2 diabetes, the American Diabetes Association (ADA) Framework uses comorbidities and functional status to categorize patients by estimated life expectancy to guide individualization of glycemic treatment. We evaluated whether modifying the ADA Framework by re...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Alexandra K, Steinman, Michael A, Lee, Sei J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523213/
https://www.ncbi.nlm.nih.gov/pubmed/32988850
http://dx.doi.org/10.1136/bmjdrc-2020-001624
_version_ 1783588344965365760
author Lee, Alexandra K
Steinman, Michael A
Lee, Sei J
author_facet Lee, Alexandra K
Steinman, Michael A
Lee, Sei J
author_sort Lee, Alexandra K
collection PubMed
description INTRODUCTION: For older adults with type 2 diabetes, the American Diabetes Association (ADA) Framework uses comorbidities and functional status to categorize patients by estimated life expectancy to guide individualization of glycemic treatment. We evaluated whether modifying the ADA Framework by removing three comorbidities and incorporating age could improve life expectancy stratification and better identify patients likely to benefit from intensive treatment. RESEARCH DESIGN AND METHODS: We examined 3166 Health and Retirement Study participants aged ≥65 with diabetes from 1998 to 2004, using a prospective cohort design with mortality follow-up through 2016. We classified participants into one of three ADA Framework categories: Healthy, Intermediate Health, and Poor Health. We created modified categories by excluding comorbidities weakly associated with mortality (hypertension, arthritis, and incontinence). Using Gompertz regression, we estimated life expectancy across age strata for both original and modified ADA Framework categories. RESULTS: The original ADA Framework classified 34% as Healthy (likely to benefit from intensive treatment), 50% as Intermediate Health, and 16% as Poor Health (unlikely to benefit from intensive treatment). Our comorbidity modification reclassified 20% of participants from Intermediate Health to Healthy. Using the modified ADA Framework, median life expectancy of the Healthy varied greatly by age (aged 65–69: 16.3 years; aged ≥80: 7.6 years), indicating differing likelihood of benefit. Additionally, age ≥80 made extended life expectancy unlikely (median life expectancy for Healthy 7.6 years, Intermediate Health 5.9 years, Poor Health 2.5 years), suggesting adults ≥80 are unlikely to benefit from intensive treatment. CONCLUSIONS: Modifying the ADA Framework by incorporating age and focusing on comorbidities associated with mortality improved life expectancy stratification, resulting in different treatment recommendations for many older adults.
format Online
Article
Text
id pubmed-7523213
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-75232132020-10-14 Improving the American Diabetes Association Framework for individualizing treatment in older adults: evaluating life expectancy Lee, Alexandra K Steinman, Michael A Lee, Sei J BMJ Open Diabetes Res Care Epidemiology/Health services research INTRODUCTION: For older adults with type 2 diabetes, the American Diabetes Association (ADA) Framework uses comorbidities and functional status to categorize patients by estimated life expectancy to guide individualization of glycemic treatment. We evaluated whether modifying the ADA Framework by removing three comorbidities and incorporating age could improve life expectancy stratification and better identify patients likely to benefit from intensive treatment. RESEARCH DESIGN AND METHODS: We examined 3166 Health and Retirement Study participants aged ≥65 with diabetes from 1998 to 2004, using a prospective cohort design with mortality follow-up through 2016. We classified participants into one of three ADA Framework categories: Healthy, Intermediate Health, and Poor Health. We created modified categories by excluding comorbidities weakly associated with mortality (hypertension, arthritis, and incontinence). Using Gompertz regression, we estimated life expectancy across age strata for both original and modified ADA Framework categories. RESULTS: The original ADA Framework classified 34% as Healthy (likely to benefit from intensive treatment), 50% as Intermediate Health, and 16% as Poor Health (unlikely to benefit from intensive treatment). Our comorbidity modification reclassified 20% of participants from Intermediate Health to Healthy. Using the modified ADA Framework, median life expectancy of the Healthy varied greatly by age (aged 65–69: 16.3 years; aged ≥80: 7.6 years), indicating differing likelihood of benefit. Additionally, age ≥80 made extended life expectancy unlikely (median life expectancy for Healthy 7.6 years, Intermediate Health 5.9 years, Poor Health 2.5 years), suggesting adults ≥80 are unlikely to benefit from intensive treatment. CONCLUSIONS: Modifying the ADA Framework by incorporating age and focusing on comorbidities associated with mortality improved life expectancy stratification, resulting in different treatment recommendations for many older adults. BMJ Publishing Group 2020-09-28 /pmc/articles/PMC7523213/ /pubmed/32988850 http://dx.doi.org/10.1136/bmjdrc-2020-001624 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Epidemiology/Health services research
Lee, Alexandra K
Steinman, Michael A
Lee, Sei J
Improving the American Diabetes Association Framework for individualizing treatment in older adults: evaluating life expectancy
title Improving the American Diabetes Association Framework for individualizing treatment in older adults: evaluating life expectancy
title_full Improving the American Diabetes Association Framework for individualizing treatment in older adults: evaluating life expectancy
title_fullStr Improving the American Diabetes Association Framework for individualizing treatment in older adults: evaluating life expectancy
title_full_unstemmed Improving the American Diabetes Association Framework for individualizing treatment in older adults: evaluating life expectancy
title_short Improving the American Diabetes Association Framework for individualizing treatment in older adults: evaluating life expectancy
title_sort improving the american diabetes association framework for individualizing treatment in older adults: evaluating life expectancy
topic Epidemiology/Health services research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523213/
https://www.ncbi.nlm.nih.gov/pubmed/32988850
http://dx.doi.org/10.1136/bmjdrc-2020-001624
work_keys_str_mv AT leealexandrak improvingtheamericandiabetesassociationframeworkforindividualizingtreatmentinolderadultsevaluatinglifeexpectancy
AT steinmanmichaela improvingtheamericandiabetesassociationframeworkforindividualizingtreatmentinolderadultsevaluatinglifeexpectancy
AT leeseij improvingtheamericandiabetesassociationframeworkforindividualizingtreatmentinolderadultsevaluatinglifeexpectancy